PVigilant Health

11/01/2026

Re-evaluating Z-Drug Safety: 50% Fatality Rate in Suicide-Related Adverse Events 🚨

​A recent deep dive into the FAERS, JADER, and CVARD databases (covering data up to 2024) has highlighted a sobering reality regarding Zopiclone and Eszopiclone.

Find out more here ⬇️
https://www.researchgate.net/publication/399584834_Suicide_adverse_events_associated_with_zopiclone_and_eszopiclone_A_pharmacovigilance_analysis_based_on_FAERS_JADER_and_CVARD

07/01/2026

⚠️ Critical Safety Update for Pediatric Practitioners & Pharmacists

​The SFDA has confirmed a voluntary precautionary recall of specific Nestle Infant Formulas (NAN, ALFAMINO, S-26 GOLD, S-26 ULTIMA) due to potential Bacillus cereus cereulide toxin contamination.
​
​Recall Date: 06 January 2026.

​The Risk: Cereulide toxins can lead to rapid-onset food poisoning.

​Provider Action: Instruct parents to stop using affected batch numbers immediately and dispose of the product.
​Stay vigilant for gastrointestinal symptoms in infants.

For detailed batch numbers, scan the official SFDA QR code or visit www.sfda.gov.sa.


​

https://www.facebook.com/share/p/16dTipcvea/

هيئة تحذّر من بعض منتجات حليب الأطفال التابعة لشركة "نستله" (NAN، ALFAMINO، S-26 GOLD، S-26 ULTIMA) لاحتمالية تلوثها بسُم "سيريوليد" الناتج عن بكتيريا "باسيلس سيريوس"، مؤكدة أن الإجراء يأتي ضمن سحب طوعي احترازي.
https://sfda.gov.sa/ar/warnings/5520880

06/01/2026

⚠️ Medical Alert & Label Update: Depo-Provera and Meningioma Risk

FDA officially approved a label update for all forms of Depo-Provera. This update introduces a warning regarding the potential risk of developing meningioma (a tumor typically arising from the membranes surrounding the brain and spinal cord) associated with long-term use of medroxyprogesterone acetate (MPA).

Review your patients' long-term contraceptive plans and ensure they are aware of the updated safety profile to help them make the most informed decisions for their health.

04/01/2026

Rethinking Moxifloxacin Safety 🏥
​Is your patient at risk for Drug‐Induced Liver Injury?

New data suggests that systematic risk stratification is essential for hospitalized patients on Moxifloxacin.

​Who is at higher risk?

​📊 Biomarkers: Patients with low albumin or elevated ALP.
​🧬 Comorbidities: Those with existing fatty liver or liver injury.
​💊 Polypharmacy: Patients also taking traditional Chinese medicine or respiratory medications.

Find out more here ⬇️
https://www.researchgate.net/publication/399236116_Drug-Induced_Liver_Injury_Associated_With_Moxifloxacin_A_Pharmacovigilance_Analysis_of_the_FDA_Adverse_Event_Reporting_System_and_a_Real-World_Retrospective_Study

​

01/01/2026

⏳️ The world of medicine is fast-paced, but our vigilance is faster. In 2026, PVigilant Health continues to bridge the gap between pharmaceutical innovation and patient security.

Happy New Year to our global healthcare community! 🌟

​

31/12/2025

🔬 The FDA landscape is evolving fast! To keep our PVigilant Health community informed, we’ve summarized the most notable novel drug approvals of 2025.

​Whether it's the first-in-class antibiotic Blujepa or the innovative pain-reliever Journavx, these drugs are set to change lives.
​
Which of these breakthroughs do you think will have the biggest impact on clinical practice this year? Let us know in the comments! 💬👇

​Save this post for your professional reference and share it with your colleagues in the medical field! 🛡️✨

​

29/12/2025

📢 Safety Alert: Is Metoclopramide still in your pediatric toolkit?

​Attention Healthcare Professionals,
​Patient safety is the core of pharmacovigilance. Recent data and regulatory updates have tightened the restrictions on Metoclopramide use in children under 10 due to serious neurological risks.
​
​🛡️ At PVigilant Health, we believe reporting is the first step to safety. Help us build a safer future by reporting any suspected ADRs.

​

25/12/2025

Is it time to update our clinical monitoring protocols for Itraconazole? 🤔

​While ITZ remains vital for systemic and cutaneous fungal infections, a recent large-scale pharmacovigilance study involving over 6 million FAERS reports has shed new light on its safety profile.

​What’s New?!
Find out more here ⬇️
https://www.researchgate.net/publication/398958592_Itraconazole-associated_adverse_events_in_fungal_infections_a_study_of_a_large_real-world_sample_based_on_the_FAERS_database_2019-2024

PVigilant_Health

23/12/2025

We are proud to announce that our Managing Director, Dr. Ahmed Hegazy, will be serving as the Co-Chair for the 5th Edition Drug Safety Symposium 2026 – Middle East Chapter. Dr. Hegazy will lead a deep dive into the practicalities of Sponsor–CRO partnerships, sharing insights on:

​▪️ Defining clear roles and responsibilities.
▪️ Implementing effective oversight strategies.
▪️ Avoiding the common pitfalls identified during inspections.

​Whether you are a Sponsor or a CRO, join us to learn what truly works in real-world PV operations.

​📅 Jan 21st-22nd | Grand Mercure Dubai City
🔗 Don’t miss this opportunity to refine your oversight and ensure compliance: https://www.drugsafetysymposium.com/reach-out/

​

20/12/2025

⚠️ ATTENTION PRESCRIBERS: Are you accidentally double-dosing NSAIDs?

​We frequently encounter a classic prescription pattern: a potent NSAID paired with a Skeletal Muscle Relaxant (SMR). While the intent is maximum pain relief, a critical pharmacological oversight often occurs when the relaxant itself contains a hidden NSAID.

​Inside this guide:
​🕵️ How to spot "Hidden" NSAIDs in common relaxants.
​📉 Why double-dosing provides zero extra benefit but double the risk.

​Expertise isn't in how many drugs we prescribe, but in how safely we use them.

Let’s protect our patients' kidneys and stomachs while we treat their joints.

​

17/12/2025

Stop chasing noise. Start finding signals. 🛑💊

​Disproportionality analysis is a staple of , but it’s often plagued by bias. How do we move from simple association to meaningful causal inference?
​
Find out more here ⬇️
https://www.researchgate.net/publication/398607996_Causal_Inference_Tools_for_Pharmacovigilance_Using_Causal_Graphs_to_Identify_and_Address_Biases_in_Disproportionality_Analysis


​

14/12/2025

⚠️ Recognizing Withdrawal Pruritus with Cetirizine & Levocetirizine

⚠️ Attention: The US Food and Drug Administration (FDA) has issued a crucial safety warning regarding the long-term use of Cetirizine and Levocetirizine (second-generation H1-antihistamines).

This advisory highlights a potentially debilitating adverse effect: Severe Rebound Pruritus following abrupt cessation after chronic use.

Protecting patients from an iatrogenic symptom is a priority.

Knowledge = Life 🌱

▶️ Follow PVIGILANT Health to receive the latest updates. Please help us extend this crucial message by sharing this post.